We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Test Detects Parasite Responsible for Trichomoniasis Infection In 15 Minutes

By LabMedica International staff writers
Posted on 27 Feb 2025
Print article
Image: The new test will make it possible to detect the parasite responsible for trichomoniasis much more quickly and inexpensively (Photo courtesy of Universitat Rovira i Virgili)
Image: The new test will make it possible to detect the parasite responsible for trichomoniasis much more quickly and inexpensively (Photo courtesy of Universitat Rovira i Virgili)

Trichomoniasis is one of the most prevalent sexually transmitted infections globally. It is caused by the parasite Trichomonas vaginalis, which is often difficult to detect as the infection is frequently asymptomatic, making diagnosis and treatment challenging. Early detection is crucial, as untreated infections can lead to reproductive health issues, increase the likelihood of HIV transmission, and cause genital tract inflammation. In response to this challenge, researchers have developed a rapid, cost-effective, and easy-to-use test for detecting the parasite. The findings from this research were published in Sensors & Diagnostics.

The test, called ALFA (Aptamer-based Lateral Flow Assay), was developed by a team from Universitat Rovira i Virgili (Tarragona, Spain) using innovative DNA aptamer technology. Aptamers are short nucleic acid sequences that can bind highly specifically to target molecules. The test employs a dual aptamer system: one aptamer is immobilized on a nitrocellulose membrane as a capturer, and the other is linked to gold nanoparticles, which generate a visual detection signal. This design helps to reduce production costs and enhances the stability of the test. One of the key benefits of this test is its affordability, costing under one euro. This makes it a viable tool for use in public health initiatives and in countries with limited healthcare resources.

The researchers demonstrated that the test can detect very low concentrations of the parasite without being confused by other common vaginal microorganisms, ensuring its accuracy. Stability is another significant advantage, as the test components retain their effectiveness for up to a year at room temperature (22 ºC), eliminating the need for refrigeration or special packaging. This feature makes the test suitable for distribution in resource-limited areas. Furthermore, the test is straightforward to use, requiring only three simple steps from sample collection to result, which can be obtained in about 15 minutes. In initial trials using clinical samples, the results were consistent with those obtained through the traditional method of direct observation. The research team plans to continue expanding its approach to detect other pathogens in the future.

Related Links:
Universitat Rovira i Virgili

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
New
H.pylori Test
Humasis H.pylori Card

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.